Rodeo Therapeutics is a pharmaceutical company founded in 2017, focusing on innovative enzyme targets and biological pathways crucial for tissue repair and regeneration. The company's primary objective is to create unique small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell recovery following bone marrow transplants. Their last investment amounting to $8.95M occurred on 26 November 2018 through a Venture Round, with the funds coming from Accelerator Corp. This highlights their potential in the Biotechnology and Pharmaceutical industries, signaling a promising pursuit of medical advancements.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $8.95M | 1 |
|
26 Nov 2018 |
| Series A | $5.90M | 9 |
|
25 Jul 2017 |
No recent news or press coverage available for Rodeo Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
